Ongoing Clinical Trials

Institution
Principal Investigator
Protocol Title
Keyword
TMU-JIRB No. Protocol Title Institution / Principal Investigator Type of Study Phases of Clinical Trials for Drugs
N202606098 A Phase 1 First-in-human Study of BGM-2121 in Patients with Advanced Solid Tumors New Drug Phase Ⅰ
N202606099 A Closed-Loop AI-Integrated Respiratory Care Platform for Home and Hospital-at-Home Settings New Medical Device NA
N202606100 A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled Multicenter Study to Evaluate the Effect of Elecoglipron in Reducing Renal Outcomes and Mortality in Participants with Chronic Kidney Disease (Elevate-CKD) New Drug Academic Research
N202606101 A Multi-national, non-interventional stUdy of bempedoic acid or its Single-pill combinAtion therapy with ezetimibe in routine clinical practice in patientS with primary Hypercholesterolaemia or mIxed dyslipidaemia – Musashi Study New Drug PMS(Post Marketing Surveillance)
N202606113 A preliminary bioequivalence study to compare two tofacitinib citrate ER tablets in healthy subjects under fed state. Bioavailability / Bioequivalence (BA/BE) NA
N202606115 Clinical Exosome Application Platform Establishment: A Study on the Safety, Tolerability, and Preliminary Exploratory Efficacy of a Human Cornea-Derived EV Eye Drop Formulation for Dry Eye Syndrome New Drug Phase Ⅰ
N202607008 Effectiveness and Safety of Home-based Respiratory Rehabilitation, IoT Monitoring, and Telehealth Risk Stratification for High-risk Post-pneumonia Patients New Medical Device NA
N202607011 A pivotal, randomized, single-dose, two-way crossover study to evaluate bioequivalence of two formulations of trientine tetrahydrochloride (150 mg trientine/tablet) after oral administration in healthy volunteers under fasting conditions New Drug NA
N202607016 A Multi-Center Clinical Study on the Application of iGood Liver AI with Ultrasonography in Automatic Detection and Diagnosis of Liver Tumors New Medical Device NA
1 2 23 24 25 26 27 28 29 30 31 32 / 32

TOP